Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Non Operating Income (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Non Operating Income for 16 consecutive years, with -$77000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income changed N/A to -$77000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$287000.0, a 26.41% increase, with the full-year FY2024 number at -$550000.0, down 49.05% from a year prior.
  • Non Operating Income was -$77000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from -$73000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $63000.0 in Q4 2023 to a low of -$1.6 million in Q4 2021.
  • A 5-year average of -$211571.4 and a median of -$75000.0 in 2025 define the central range for Non Operating Income.
  • Biggest YoY gain for Non Operating Income was 164.29% in 2023; the steepest drop was 14300.0% in 2023.
  • NovaBay Pharmaceuticals' Non Operating Income stood at -$1.6 million in 2021, then surged by 93.79% to -$98000.0 in 2022, then surged by 164.29% to $63000.0 in 2023, then tumbled by 253.97% to -$97000.0 in 2024, then rose by 20.62% to -$77000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Non Operating Income are -$77000.0 (Q3 2025), -$73000.0 (Q2 2025), and -$40000.0 (Q1 2025).